206 related articles for article (PubMed ID: 27807478)
1. A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis.
Yue X; Zhao Y; Huang G; Li J; Zhu J; Feng Z; Hu W
Cell Discov; 2016; 2():16039. PubMed ID: 27807478
[TBL] [Abstract][Full Text] [Related]
2. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
3. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
Nat Commun; 2013; 4():2996. PubMed ID: 24356649
[TBL] [Abstract][Full Text] [Related]
4. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
5. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
6. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
[TBL] [Abstract][Full Text] [Related]
7. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
8. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R; Moll UM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
11. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
14. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.
Cooks T; Pateras IS; Jenkins LM; Patel KM; Robles AI; Morris J; Forshew T; Appella E; Gorgoulis VG; Harris CC
Nat Commun; 2018 Feb; 9(1):771. PubMed ID: 29472616
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
[TBL] [Abstract][Full Text] [Related]
17. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.
Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T
Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703
[TBL] [Abstract][Full Text] [Related]
18. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
19. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
[TBL] [Abstract][Full Text] [Related]
20. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
